Síndrome nefrótico como manifestación de microangiopatía trombótica secundaria al uso crónico de sunitinib
| Autor: | Luis F. Arias, Lina María Serna-Higuita, Camilo Andrés García-Prada, Dahyana Cadavid-Aljure, Arbey Aristizabal-Alzate, Gustavo Adolfo Zuluaga-Valencia, John Fredy Nieto-Ríos |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Thrombotic microangiopathy Proteinuria Sunitinib business.industry medicine.medical_treatment Glomerulonephritis urologic and male genital diseases medicine.disease Gastroenterology Nephrology Internal medicine medicine Minimal change disease medicine.symptom Stromal tumor business Nephrotic syndrome medicine.drug |
| Zdroj: | Nefrología. 42:722-726 |
| ISSN: | 0211-6995 |
| DOI: | 10.1016/j.nefro.2021.08.004 |
| Popis: | Nephrotic syndrome in patients with cancer may be related to the primary malignancy or chemotherapeutic therapy. Solid organ cancers may cause membranous glomerulonephritis manifesting with nephrotic syndrome; other less common histologic presentations include focal and segmental glomerulosclerosis and minimal change disease. In addition, chemotherapy agents can cause renal toxicity by affecting the small blood vessels, glomeruli, tubules, and interstitium. Tyrosine kinase inhibitors such as sunitinib may cause endothelial and podocyte damage leading to renal limited thrombotic microangiopathy, manifested by proteinuria and hypertension. We report a case of an elderly man with gastrointestinal stromal tumor (GIST) on treatment with sunitinib who had as a complication of a thrombotic microangiopathy manifested with nephrotic syndrome and difficult-to-control hypertension, which was controlled by stopping this drug but with a fatal outcome due to its malignant neoplasm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|